EWTX
Edgewise Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$37.92
+1.96%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -21.4%
- EBIT
- -25.4%
- EPS
- -19.4%
- Free cash flow
- -27.0%
- Operating cash flow
- -27.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +42.9%
- EPS
- +1.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- -25.9%
- EBIT
- -20.5%
- Net income
- -25.4%
- EPS
- -12.4%
- Free cash flow
- -30.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026